vs
Merchants Bancorp（MBIN）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Merchants Bancorp的1.3倍（$219.9M vs $175.2M），Merchants Bancorp净利率更高（38.6% vs -1.0%，领先39.7%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 4.8%）
Ameris Bancorp是总部位于美国佐治亚州亚特兰大的银行控股企业，旗下设有Ameris Bank子公司，在佐治亚州、阿拉巴马州、佛罗里达州、北卡罗来纳州、南卡罗来纳州运营全服务网点，同时在上述五州及弗吉尼亚州、马里兰州、田纳西州设立仅办理抵押贷款业务的网点，为个人和企业客户提供线上及移动端银行服务。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
MBIN vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.3倍
$175.2M
净利率更高
MBIN
高出39.7%
-1.0%
两年增速更快
OFIX
近两年复合增速
4.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $175.2M | $219.9M |
| 净利润 | $67.7M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 38.6% | -1.0% |
| 营收同比 | — | 2.0% |
| 净利润同比 | 16.3% | 92.4% |
| 每股收益（稀释后） | $1.25 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MBINOFIX
| Q1 26 | $175.2M | — | ||
| Q4 25 | $185.3M | $219.9M | ||
| Q3 25 | $171.1M | $205.6M | ||
| Q2 25 | $179.2M | $203.1M | ||
| Q1 25 | $145.9M | $193.6M | ||
| Q4 24 | $193.8M | $215.7M | ||
| Q3 24 | $149.6M | $196.6M | ||
| Q2 24 | $159.5M | $198.6M |
净利润MBINOFIX
| Q1 26 | $67.7M | — | ||
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $54.7M | $-22.8M | ||
| Q2 25 | $38.0M | $-14.1M | ||
| Q1 25 | $58.2M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $61.3M | $-27.4M | ||
| Q2 24 | $76.4M | $-33.4M |
毛利率MBINOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% |
营业利润率MBINOFIX
| Q1 26 | — | — | ||
| Q4 25 | 39.9% | 0.2% | ||
| Q3 25 | 37.8% | -8.3% | ||
| Q2 25 | 27.3% | -7.9% | ||
| Q1 25 | 52.4% | -25.2% | ||
| Q4 24 | 66.0% | -5.3% | ||
| Q3 24 | 54.4% | -9.6% | ||
| Q2 24 | 62.2% | -12.5% |
净利率MBINOFIX
| Q1 26 | 38.6% | — | ||
| Q4 25 | — | -1.0% | ||
| Q3 25 | 32.0% | -11.1% | ||
| Q2 25 | 21.2% | -6.9% | ||
| Q1 25 | 39.9% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | 41.0% | -13.9% | ||
| Q2 24 | 47.9% | -16.8% |
每股收益（稀释后）MBINOFIX
| Q1 26 | $1.25 | — | ||
| Q4 25 | $1.28 | $-0.05 | ||
| Q3 25 | $0.97 | $-0.57 | ||
| Q2 25 | $0.60 | $-0.36 | ||
| Q1 25 | $0.93 | $-1.35 | ||
| Q4 24 | $1.84 | $-0.76 | ||
| Q3 24 | $1.17 | $-0.71 | ||
| Q2 24 | $1.49 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $83.2M | $82.0M |
| 总债务越低越好 | $32.0M | — |
| 股东权益账面价值 | $2.3B | $450.0M |
| 总资产 | $20.3B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资MBINOFIX
| Q1 26 | $83.2M | — | ||
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M |
总债务MBINOFIX
| Q1 26 | $32.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益MBINOFIX
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | $450.0M | ||
| Q3 25 | $2.2B | $442.5M | ||
| Q2 25 | $2.2B | $458.3M | ||
| Q1 25 | $2.2B | $458.3M | ||
| Q4 24 | $2.2B | $503.1M | ||
| Q3 24 | $1.9B | $525.9M | ||
| Q2 24 | $1.9B | $546.0M |
总资产MBINOFIX
| Q1 26 | $20.3B | — | ||
| Q4 25 | $19.4B | $850.6M | ||
| Q3 25 | $19.4B | $832.6M | ||
| Q2 25 | $19.1B | $837.2M | ||
| Q1 25 | $18.8B | $823.1M | ||
| Q4 24 | $18.8B | $893.3M | ||
| Q3 24 | $18.7B | $867.9M | ||
| Q2 24 | $18.2B | $882.0M |
负债/权益比MBINOFIX
| Q1 26 | 0.01× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流MBINOFIX
| Q1 26 | — | — | ||
| Q4 25 | $-341.2M | $27.7M | ||
| Q3 25 | $29.8M | $12.4M | ||
| Q2 25 | $-121.2M | $11.6M | ||
| Q1 25 | $148.0M | $-18.4M | ||
| Q4 24 | $-835.3M | $23.7M | ||
| Q3 24 | $-492.6M | $11.7M | ||
| Q2 24 | $51.1M | $9.0M |
自由现金流MBINOFIX
| Q1 26 | — | — | ||
| Q4 25 | $-362.2M | $16.8M | ||
| Q3 25 | $24.0M | $2.5M | ||
| Q2 25 | $-125.7M | $4.5M | ||
| Q1 25 | $141.2M | $-25.1M | ||
| Q4 24 | $-853.7M | $15.2M | ||
| Q3 24 | $-497.2M | $6.3M | ||
| Q2 24 | $45.8M | $-360.0K |
自由现金流率MBINOFIX
| Q1 26 | — | — | ||
| Q4 25 | -195.5% | 7.6% | ||
| Q3 25 | 14.0% | 1.2% | ||
| Q2 25 | -70.1% | 2.2% | ||
| Q1 25 | 96.8% | -13.0% | ||
| Q4 24 | -440.6% | 7.0% | ||
| Q3 24 | -332.4% | 3.2% | ||
| Q2 24 | 28.7% | -0.2% |
资本支出强度MBINOFIX
| Q1 26 | — | — | ||
| Q4 25 | 11.3% | 4.9% | ||
| Q3 25 | 3.4% | 4.8% | ||
| Q2 25 | 2.5% | 3.5% | ||
| Q1 25 | 4.7% | 3.5% | ||
| Q4 24 | 9.5% | 4.0% | ||
| Q3 24 | 3.0% | 2.7% | ||
| Q2 24 | 3.3% | 4.7% |
现金转化率MBINOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | -3.19× | — | ||
| Q1 25 | 2.54× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -8.04× | — | ||
| Q2 24 | 0.67× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MBIN
| Net Interest Income | $128.6M | 73% |
| Noninterest Income | $46.6M | 27% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
